Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GSK’s China Revenues May Be Down by 30% in Q3

publication date: Sep 24, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China revenues for GlaxoSmithKline may drop as much as 30% in the third quarter, according to estimates from Citigroup, which cited feedback from industry sources. GSK is experiencing negative fallout from its three-month bribery scandal. Doctors are refusing to see the company’s sales reps, because they don’t want to be accused of any wrongdoing. And the revenue shortfall may affect other multinationals by the same 30%, said Citigroup, as doctors avoid the products of all foreign companies, even if the particular company has not been accused of corruption. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...